Aktis Oncology (NASDAQ:AKTS) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Aktis Oncology (NASDAQ:AKTS) posted its quarterly earnings results on Thursday. The technology company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.07), FiscalAI reports. The firm had revenue of $3.91 million during the quarter, compared to analyst estimates of $4.80 million.

Aktis Oncology Price Performance

Shares of NASDAQ AKTS opened at $16.00 on Friday. The company has a 50-day simple moving average of $18.74 and a 200-day simple moving average of $20.81. The company has a market cap of $860 million and a PE ratio of -19.51. Aktis Oncology has a 12 month low of $13.96 and a 12 month high of $34.19.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Weiss Ratings cut Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 2nd. Oppenheimer began coverage on Aktis Oncology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $40.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $35.00 target price on shares of Aktis Oncology in a report on Friday, October 2nd. Wall Street Zen cut Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Finally, BMO Capital Markets assumed coverage on Aktis Oncology in a research note on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.62.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.